Evaluate the therapeutic properties of a peroxy pyruvic acid (PPA)-containing topical anti-infective in a human ex-vivo model that replicates the natural conditions of a human chronic wound.
Approach:
Wound material was extracted from patients with nonhealing diabetic ulcers, venous stasis ulcers, and arterial wounds. Microbial species were identified, and wound colonization was quantified. Extracted samples were then exposed to a PPA-containing topical anti-infective as an instillation solution with negative pressure wound therapy NPWT at concentrations of 1,000, 1,500, or 2,500 ppm for a period of 1, 5, or 10 min to determine the effect of exposure on isolated pathogens, including effect on proteins.
Results:
A total of 32 samples were collected from patients. Samples presented with a range of bacteria and fungi representing 14 genera and 22 species, many of which are or are evolving to be resistant to many, if not most, current systemic antibiotics. Thirteen of twenty-three samples (57%) from chronic wounds had bacteria counts ≥105 and most were 6 logs or more. Seven of 10 samples (70%) from acute wounds had bacteria counts ≤105 and most were much lower. Exposure to PPA-containing topical anti-infective at 1,000 ppm killed all bacteria and fungi in all samples within 1 min of exposure.
Innovation:
PPA-containing topical anti-infective is a potentially valuable clinical option for NPWT.
Conclusion:
PPA-containing topical anti-infective is a potential candidate for use as an NPWT instillation solution for the treatment of wound infections caused by susceptible pathogens.
Get full access to this article
View all access options for this article.
References
1.
WerdinF, TennenhausM, SchallerHE, RennekampffHO. Evidence-based management strategies for treatment of chronic wounds. Eplasty, 2009; 9:e19.
BolleroD, DeganoK, GangemiEN, AlojD, MalvasioV, StellaM. Long-term follow-up of negative pressure wound therapy with instillation: a limb salvage procedure?. Int Wound J, 2014; [Epub head of print]; DOI: 10.1111/iwj.12373.
7.
RycerzAM, AllenD, LessingMC. Science supporting negative pressure wound therapy with instillation. Int Wound J, 2013; 10:20–24.
8.
BackDA, Scheuemann-PoleyC, WillyC. Recommendations on negative pressure wound therapy with instillation and anti-microbial solutions—when, where and how to use: what does the evidence show?. Int Wound J, 2013; 10:32–42.
9.
MatiasekJ, DjedovicG, MattesichM, et al.The combined use of NPWT and instillation using and octenide based wound rinsing solution: a case study. J Wound Care, 2014; 23:590–596.
10.
GuptaS, GabrielA, LantisJ, TéotL. Clinical recommendations and practical guide for negative pressure wound therapy with instillation. Int Wound J, 2015; [Epub ahead of print]; DOI: 10.1111/iwj.12452.
11.
D'AtanasioN, Capezzone de JoannonA, ManganoG, et al.A new acid-oxidizing solution: assessment of its role on methicillin-resistant Staphylococcus aureus (MRSA) biofilm morphological changes. Wounds, 2015; 27:265–273.
12.
FonderMA, LazarusGS, CowanDA, Aronson-CookB, KohliAR, MamelakAJ. Treating the chronic wound: a practical approach to the care of nonhealing wounds and wound care dressings. J Am Acad Dermatol, 2008; 58:185–206.
13.
Rodriquez-MenocalL, ShareefS. Salgado M, Shabbir A, Van Badiavas E. Role of whole bone marrow, whole bone marrow cultured cells, and mesenchymal stem cells in chronic wound healing. Stem Cell Res Ther, 2015; 6:24.
RhoadsDD, CoxSB, ReesEJ, SunY, WolcottRD. Clinical identification of bacteria in human chronic wound infections: culturing vs. 16S ribosomal DNA sequencing. BMC Infect Dis, 2012; 12:321.
16.
de SouzaJM, VieiraÉC, CortezTM, MondelliAL, MiotHA, AbbadeLP. Clinical and microbiologic evaluation of chronic leg ulcers: a cross-sectional study. Adv Skin Wound Care, 2014; 27:222–227.
17.
DanaAN, BaumanWA. Bacteriology of pressure ulcers in individuals with spinal cord injury: what we know and what we should know. J Spinal Cord Med, 2015; 38:147–160.
18.
Cornejo-JuárezP, Vilar-CompteD, Pérez-JiménezC, Ñamendys-SilvaSA, Sandoval-HernándezS, Volkow-FernándezP. The impact of hospital-acquired infections with multidrug-resistant bacteria in an oncology intensive care unit. Int J Infect Dis, 2015; 31:31–34.
19.
PodkowikM, BystrońJ, BaniaJ. Genotypes, antibiotic resistance, and virulence factors of staphylococci from ready-to-eat food. Foodborne Pathog Dis, 2012; 9:91–93.
20.
KloosWE, BannermanTL. Update on clinical significance of coagulase-negative Staphylococci. Clin Microbiol Rev, 1994; 7:117–140.
21.
MalesBM, BartholomewWR, AmsterdamD. Staphylococcus simulans septicemia in a patient with chronic osteomylitis and pyrathrosis. J Clin Microbiol, 1985; 21:255–257.
22.
MalletM, LoiezC, MelliezH, YazdanpanahY, SennevilleE, LemaireX. Staphylococcus simulans as an authentic pathogenic agent of osteoarticular infections. Infection, 2011; 39:473–476.
23.
BernardP, JarlierV, Santerre-HenriksenA. Antibiotic susceptibility of Staphylococcus aureus strains responsible for community-acquired skin infections. Ann Dermatol Venereol, 2008; 135:13–19.
SerraR, GrandeR, BuffoneG, et al.Extracellular matrix assessment of infected chronic venous leg ulcers: role of metalloproteinases and inflammatory cytokines. Int Wound J, 2014; [Epub ahead of print]; DOI: 10.1111/iwj.12225.
26.
BottoneEJ, FabbriM, AshrafA. Corynebacterium striatum: chronic infection of a cutaneous ulcer in a patient with AIDS. Rev Infect, 2010; 1:104–109.
27.
TendolkarPM, BaghdayanAS, ShankarN. Pathogenic enterococci: new developments in the 21st century. Cell Mol Life Sci, 2003; 60:2622–2636.
WerthBJ, HahnWO, Butler-WuSM, RakitaRM. Emergence of high-level daptomycin resistance in Corynebacterium striatum in two patients with left ventricular assist device infections. Microb Drug Resist, 2015;[Epub ahead of print]; DOI: 10.1089/mdr.2015.0208.
30.
YooG, KimJ, UhY, LeeHG, HwangGY, YoonKJ. Multidrug-resistant Corynebacterium striatum bacteremia: first case in Korea. Ann Lab Med, 2015; 35:472–473.
31.
NeasE, Chambers Am. Prevalence of antibiotic resistance and potential suitability of a new antimicrobial for wound treatment. Poster F-232. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Diego, CA.September 17–21, 2015.
32.
MedellM, HartM, BatistaML. In vitro antimicrobial susceptibility in Enterococcus faecalis and Enterococcus faecium isolated from hospitalized patients. Biomedica, 2014; 34:50–57.
33.
ShimazuK, OquchiR, TakahashiY, KonishiK, KaribeH.Effects of surface reaction-type pre-reacted glass ionomer on oral biofilm formation of Streptococcus gordonii. Odontology 2015; [Epub ahead of print]; DOI: https://dx-doi-org.web.bisu.edu.cn/10.1007/s10266-015-0217-2.
34.
BachmeyerC, LandgrafN, DaumasL. Soft tissue infection caused by Gemella morbillorum in two intravenous drug users. J Am Acad Dermatol, 2005; 52:705–706.
35.
VignierN, CouzigouC, Nguyen VanJC, et al.Diagnosis and treatment strategies for community-acquired Streptococcus salivarius meningitis. Med Mal Infect, 2014; 44:42–44.
36.
WilsonM, MartinR, WalkST, et al.Clinical and laboratory features of Streptococcus salivarius meningitis: a case report and literature review. Clin Med Res, 2012; 10:15–25.
37.
TurkS, MazzoliS, StšepetovaJ, KuznetsovaJ, MändarR. Coryneform bacteria in human semen: inter-assay variability in species composition detection and biofilm production ability. Microb Ecol Health Dis, 2014; 25 [Epub ahead of print]; DOI: 10.3402/mehd.v25.22701.
38.
ShanksRM, DashiffA, AlsterJS, KadouriDE. Isolation and identification of a bacteriocin with antibacterial and antibiofilm activity from Citrobacter freundii. Arch Microbiol, 2012; 194:575–587.
39.
BottoneEJ.Bacillus cereus, a volatile human pathogen. Clin Microbiol Rev, 2010; 23:382–398.
40.
PittTL, McClureJ, ParkerMD, AmézquitaA, McClurePJ. Bacillus cereus in personal care products: risk to consumers. Int J Cosmet Sci, 2015; 37:165–174.
41.
BonhommeJ, ChauvelM, GoyardS, RouxP, RossignolT, d'EnfertC. Contribution of the glycolytic flux and hypoxia adaptation to efficient biofilm formation by Candida albicans. Mol Microbiol, 2011; 80:995–1013.
42.
GiráldezP, MayoE, PavónP, LosadaA. [Skin infection due to Serratia marcescens in an immunocompetent patient]. Actas Dermosifiliogr, 2011; 102:236–237 (Article in Spanish).
43.
HejaziA, AuckenHM, FalkinerFR. Epidemiology and susceptibility of Serratia marcescens in a large general hospital over an 8-year period. J Hosp Infect, 2000; 45:42–46.
44.
SeijaV, Medina PresentadoJC, BadoI, et al.Sepsis caused by New Delhi metallo-β-lactamase (blaNDM-1) and qnrD-producing Morganella morganii, treated successfully with fosfomycin and meropenem: case report and literature review. Int J Infect Dis, 2015; 30:20–26.
45.
MontraversP, BassettiM, DupontH, et al.Efficacy of tigecycline for the treatment of complicated skin and soft-tissue infections in real-life clinical practice from five European observational studies. J Antimicrob Chemother, 2013; 68:ii15–ii24.
46.
SuissaD, DaninoA, NikolisA. Negative-pressure therapy versus standard wound care: a meta-analysis of randomized trials. Plast Reconstr Surg, 2011; 128:488–504.
47.
DavisSC, RicottiC, CazzanigaA, WelshE, EaglsteinWH, MertzPM. Microscopic and physiologic evidence for biofilm-associated wound colonization in vivo. Wound Repair Regen, 2008; 16:23–29.
48.
MaL, GaoY, MaressoAW. A free radical-based killing mechanism of E. coli that is driven by a unique combination of iron restriction and certain antibiotics. J Bacteriol, 2015; [Epub ahead of print]; DOI: 10.1128/JB.00758-15.
49.
WarrenL.Review of Medical Microbiology and Immunology, 11th ed. New York, NY: McGraw Hill, 2010.
50.
KimJ, SudberyP. Candida albicans, a major human fungal pathogen. J Microbiol, 2011; 49:171–177.
51.
SoriaX, BielsaI, RiberaM, et al.Acute dermal absecesses caused by Serratia marcescens. J Am Acad Dermatol, 2008; 58:891–893.
52.
O'HaraCM, BrennerFW, MillerJM. Classification, identification, and clinical significance of Proteus, Providencia, and Morgnaella. Clin Microbiol Rev, 2000; 13:534–546.
